Psychoeducational Groups for Adults With ADHD

Overview

This pilot study aims to assess patient satisfaction and preliminary efficacy of a psychoeducational group treatment, using a randomized waitlist-controlled trial, at two different outpatient clinics in mid-Norway. All participants will receive standard treatment during the intervention period. Assessment of client satisfaction (CSQ 8), general self-efficacy (GSE-6), ADHD-related quality of life (AAQoL) symptoms of ADHD (SCL-9; ASRS), and work participation will be conducted at time of recruitment prior to randomization (T0), pre- (T1), post-treatment (T2), with a 10 week follow-up.

Full Title of Study: “Psychoeducational Groups for Adults With Attention-Deficit Hyperactivity/Impulsivity Disorder (ADHD): a Randomized Waitlist-controlled Multicenter Pilot Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 15, 2019

Interventions

  • Behavioral: Psychoeducational group therapy
    • The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
  • Behavioral: Waiting list
    • Waiting list and standard treatment (ADHD treatment as usual)
  • Other: Standard treatment
    • Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.

Arms, Groups and Cohorts

  • Experimental: psychoeducational groups
    • Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
  • Active Comparator: Waiting list
    • Waiting list and standard treatment (ADHD treatment as usual)

Clinical Trial Outcome Measures

Primary Measures

  • Change in patient satisfaction
    • Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
    • Measured with a modified version of the Client Satisfaction Questionnaire (CSQ-8). The scale consists of 8 items measured on a scale from 1 to 4. A sum score between 8 and 32 indicate the level of satisfaction with services provided.
  • Change in general self-efficacy
    • Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
    • Measured with General Self-Efficacy Scale (GSE-6), a short-form measure of self-efficacy. Self-efficacy is regarded as a protective factor in adapting to stress and chronic illness. The scale consists of 6 items, measured on a 4-point scale, with a possible range of 6-24.

Secondary Measures

  • Change in ADHD-related symptoms (ASRS)
    • Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
    • Measured with ASRS, a self-reporting scale for ADHD-related symptoms in adults. The scale consists of 18 items, based on DSM-V diagnostic criteria for ADHD. The items are measured on a 5-point scale, with a possible range of 0-72.
  • Change in ADHD-related symptoms (SCL-9)
    • Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
    • Measured with 9 items from the SCL-90. SCL-9 is an ADHD-specific scale, consisting of 9 items of the original 90. SCL-9 covers the specific characteristic traits of ADHD.
  • Change in ADHD-related quality of life
    • Time Frame: Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)
    • Measured with AAQoL – which covers ADHD-specific quality of life and function. AAQoL consists of 29 questions measuring health related quality of life among adults with ADHD.

Participating in This Clinical Trial

Inclusion Criteria

  • confirmed ADHD diagnosis – speaking a Scandinavian language Exclusion Criteria:

  • not able or willing to give informed consent – psychosis – severe learning difficulties

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 67 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Norwegian University of Science and Technology
  • Collaborator
    • Helse Nord-Trøndelag HF
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Terje Torgersen, phd, Principal Investigator, St. Olavs Hospital

References

Vaag JR, Lara-Cabrera ML, Hjemdal O, Gjervan B, Torgersen T. Psychoeducational groups versus waitlist in treatment of attention-deficit hyperactivity/impulsivity disorder (ADHD) in adults: a protocol for a pilot randomized waitlist-controlled multicenter trial. Pilot Feasibility Stud. 2019 Jan 23;5:17. doi: 10.1186/s40814-019-0401-1. eCollection 2019.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.